Coeptis Therapeutics logo

Coeptis TherapeuticsNASDAQ: COEP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

17 December 2020

Next earnings report:

09 August 2024

Last dividends:

N/A

Next dividends:

N/A
$10.65 M
-91%vs. 3y high
18%vs. sector
-vs. 3y high
-vs. sector
-93%vs. 3y high
64%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 03 Jul 2024 18:24:09 GMT
$0.29+$0.02(+6.26%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

COEP Latest News

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering
prnewswire.com20 June 2024 Sentiment: -

Bolsters Company's Corporate Mission Financing Led by Board Member and Priced at Premium to Market Price WEXFORD, Pa. , June 20, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce that it has closed on $4.3 million in a financing led by CJC Investment Trust, an entity controlled by board member Christopher Calise.

Why Is Coeptis Therapeutics (COEP) Stock Up 14% Today?
InvestorPlace27 March 2023 Sentiment: POSITIVE

Coeptis Therapeutics (NASDAQ: COEP ) stock is climbing higher on Monday despite a lack of news from the drug company. Investors searching for the reason why COEP stock is up today won't find much news.

What type of business is Coeptis Therapeutics?

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.

What sector is Coeptis Therapeutics in?

Coeptis Therapeutics is in the Healthcare sector

What industry is Coeptis Therapeutics in?

Coeptis Therapeutics is in the Biotechnology industry

What country is Coeptis Therapeutics from?

Coeptis Therapeutics is headquartered in United States

When did Coeptis Therapeutics go public?

Coeptis Therapeutics initial public offering (IPO) was on 17 December 2020

What is Coeptis Therapeutics website?

https://coeptispharma.com

Is Coeptis Therapeutics in the S&P 500?

No, Coeptis Therapeutics is not included in the S&P 500 index

Is Coeptis Therapeutics in the NASDAQ 100?

No, Coeptis Therapeutics is not included in the NASDAQ 100 index

Is Coeptis Therapeutics in the Dow Jones?

No, Coeptis Therapeutics is not included in the Dow Jones index

When does Coeptis Therapeutics report earnings?

The next expected earnings date for Coeptis Therapeutics is 09 August 2024